Dr. Scherber on the Treatment of Myelofibrosis

Video

Robyn M. Scherber, MD, MPH, physician, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the treatment of patients with myelofibrosis.

Robyn M. Scherber, MD, MPH, physician, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the treatment of patients with myelofibrosis.

Scherber says that the treatment approach to myelofibrosis is 2-fold. First, risk must be assessed. Risk scoring methods such as the Dynamic International Prognostic Scoring System are often used, and if the patient is early on in their course of disease, Scherber says she uses the International Prognostic Score. Once risk is determined, the treatment paradigm becomes clearer.

The other thing that is considered when choosing treatment for a patient with myelofibrosis is symptom burden. MPN10 is a 10-item assessment of symptoms with a 0 to 100 scoring system. If the collective total of the symptoms is greater than 20 out of 100, or any individual symptom is scored greater than 5, those patients may benefit from symptom-based therapy, explains Scherber.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD